{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:22:05Z","timestamp":1789399325161,"version":"build-2803163510"},"reference-count":50,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":4192,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Compelling epidemiological and clinical evidence has identified a specific cardiomyopathy in diabetes, characterized by early diastolic dysfunction and adverse structural remodeling. Activation of the insulin-like growth factor 1 (IGF-1) receptor (IGF-1R) promotes physiological cardiac growth and enhances contractile function. The aim of the present study was to examine whether cardiac-specific overexpression of IGF-1R prevents diabetes-induced myocardial remodeling and dysfunction associated with a murine model of diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Type 1 diabetes was induced in 7-week-old male IGF-1R transgenic mice using streptozotocin and followed for 8 weeks. Diastolic and systolic function was assessed using Doppler and M-mode echocardiography, respectively, in addition to cardiac catheterization. Cardiac fibrosis and cardiomyocyte width, heart weight index, gene expression, Akt activity, and IGF-1R protein content were also assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Nontransgenic (Ntg) diabetic mice had reduced initial (E)-to-second (A) blood flow velocity ratio (E:A ratio) and prolonged deceleration times on Doppler echocardiography compared with nondiabetic counterparts, indicative markers of diastolic dysfunction. Diabetes also increased cardiomyocyte width, collagen deposition, and prohypertrophic and profibrotic gene expression compared with Ntg nondiabetic littermates. Overexpression of the IGF-1R transgene markedly reduced collagen deposition, accompanied by a reduction in the incidence of diastolic dysfunction. Akt phosphorylation was elevated \u223c15-fold in IGF-1R nondiabetic mice compared with Ntg, and this was maintained in a setting of diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>The current study suggests that cardiac overexpression of IGF-1R prevented diabetes-induced cardiac fibrosis and diastolic dysfunction. Targeting IGF-1R\u2013Akt signaling may represent a therapeutic target for the treatment of diabetic cardiac disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/db09-1456","type":"journal-article","created":{"date-parts":[[2010,3,10]],"date-time":"2010-03-10T02:09:43Z","timestamp":1268186983000},"page":"1512-1520","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":131,"title":["Cardiac-Specific IGF-1 Receptor Transgenic Expression Protects Against Cardiac Fibrosis and Diastolic Dysfunction in a Mouse Model of Diabetic Cardiomyopathy"],"prefix":"10.2337","volume":"59","author":[{"given":"Karina","family":"Huynh","sequence":"first","affiliation":[{"name":"From the Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia, and the Department of Medicine, Monash University, Melbourne, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"McMullen","sequence":"additional","affiliation":[{"name":"From the Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia, and the Department of Medicine, Monash University, Melbourne, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey L.","family":"Julius","sequence":"additional","affiliation":[{"name":"From the Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia, and the Department of Medicine, Monash University, Melbourne, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Win","family":"Tan","sequence":"additional","affiliation":[{"name":"From the Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia, and the Department of Medicine, Monash University, Melbourne, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane E.","family":"Love","sequence":"additional","affiliation":[{"name":"From the Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia, and the Department of Medicine, Monash University, Melbourne, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Cemerlang","sequence":"additional","affiliation":[{"name":"From the Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia, and the Department of Medicine, Monash University, Melbourne, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Kiriazis","sequence":"additional","affiliation":[{"name":"From the Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia, and the Department of Medicine, Monash University, Melbourne, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Du","sequence":"additional","affiliation":[{"name":"From the Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia, and the Department of Medicine, Monash University, Melbourne, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca H.","family":"Ritchie","sequence":"additional","affiliation":[{"name":"From the Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia, and the Department of Medicine, Monash University, Melbourne, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2010,3,9]]},"reference":[{"key":"2022031222485915500_B1","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.2337\/diacare.21.9.1414","article-title":"Global burden of diabetes, 1995\u20132025: prevalence, numerical estimates, and projections","volume":"21","author":"King","year":"1998","journal-title":"Diabetes Care"},{"key":"2022031222485915500_B2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/414782a","article-title":"Global and societal implications of the diabetes epidemic","volume":"414","author":"Zimmet","year":"2001","journal-title":"Nature"},{"key":"2022031222485915500_B3","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/S0140-6736(08)60767-9","article-title":"Type 1 diabetes, hyperglycaemia, and the heart","volume":"371","author":"Retnakaran","year":"2008","journal-title":"Lancet"},{"key":"2022031222485915500_B4","first-page":"343","article-title":"Cardiovascular dysfunction in insulin-dependent and non-insulin-dependent animal models of diabetes mellitus","author":"Pierce","year":"1996"},{"key":"2022031222485915500_B5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am J Cardiol"},{"key":"2022031222485915500_B6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0002-9149(91)90716-X","article-title":"Echocardiography evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham-heart study)","volume":"68","author":"Galderisi","year":"1991","journal-title":"Am J Cardiol"},{"key":"2022031222485915500_B7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0002-9149(00)01366-7","article-title":"Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus","volume":"87","author":"Zabalgoitia","year":"2001","journal-title":"Am J Cardiol"},{"key":"2022031222485915500_B8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000064682","article-title":"Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy","volume":"98","author":"Schannwell","year":"2002","journal-title":"Cardiology"},{"key":"2022031222485915500_B9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S1071-9164(99)91337-4","article-title":"Noninvasive evaluation of cardiac dysfunction by echocardiography in streptozotocin-induced diabetic rats","volume":"5","author":"Hoit","year":"1999","journal-title":"J Card Fail"},{"key":"2022031222485915500_B10","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1042\/CS20030168","article-title":"Subclinical left ventricular dysfunction in asymptomatic patients with Type II diabetes mellitus, related to serum lipids and glycated haemoglobin","volume":"105","author":"Vinereanu","year":"2003","journal-title":"Clin Sci"},{"key":"2022031222485915500_B11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/jcp.46.1.32","article-title":"Collagen remodelling in myocardia of patients with diabetes","volume":"46","author":"Shimizu","year":"1993","journal-title":"J Clin Path"},{"key":"2022031222485915500_B12","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1161\/01.CIR.101.8.899","article-title":"Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model","volume":"101","author":"Mizushige","year":"2000","journal-title":"Circulation"},{"key":"2022031222485915500_B13","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.2337\/diabetes.52.9.2389","article-title":"B-type natriuretic peptide prevents acute hypertrophic responses in the diabetic rat heart: importance of cyclic GMP","volume":"52","author":"Rosenkranz","year":"2003","journal-title":"Diabetes"},{"key":"2022031222485915500_B14","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1161\/01.CIR.101.19.2271","article-title":"Impact of diabetes on cardiac structure and function: the strong heart study","volume":"101","author":"Devereux","year":"2000","journal-title":"Circulation"},{"key":"2022031222485915500_B15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1440-1681.2007.04585.x","article-title":"Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure","volume":"34","author":"McMullen","year":"2007","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2022031222485915500_B16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tem.2005.03.011","article-title":"Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance","volume":"16","author":"Ranke","year":"2005","journal-title":"Trends Endocrinol Metab"},{"key":"2022031222485915500_B17","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1172\/JCI117706","article-title":"Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure","volume":"95","author":"Duerr","year":"1995","journal-title":"J Clin Invest"},{"key":"2022031222485915500_B18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1677\/joe.0.1800175","article-title":"Transgenic overexpression of insulin-like growth factor I prevents streptozotocin-induced cardiac contractile dysfunction and beta-adrenergic response in ventricular myocytes","volume":"180","author":"Norby","year":"2004","journal-title":"J Endocrinol"},{"key":"2022031222485915500_B19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1440-1681.2007.04873.x","article-title":"Role of insulin-like growth factor 1 and phosphoinositide 3-kinase in a setting of heart disease","volume":"35","author":"McMullen","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2022031222485915500_B20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1161\/01.RES.0000013780.77774.75","article-title":"Cardiac-specific IGF-1 expression attenuates dilated cardiomyopathy in tropomodulin-overexpressing transgenic mice","volume":"90","author":"Welch","year":"2002","journal-title":"Circ Res"},{"key":"2022031222485915500_B21","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1161\/01.RES.84.9.1007","article-title":"Insulin-like growth factor-1 attenuates the detrimental impact of nonocclusive coronary artery constriction on the heart","volume":"84","author":"Li","year":"1999","journal-title":"Circ Res"},{"key":"2022031222485915500_B22","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI119730","article-title":"Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy","volume":"100","author":"Li","year":"1997","journal-title":"J Clin Invest"},{"key":"2022031222485915500_B23","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.2337\/diabetes.50.6.1414","article-title":"IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress","volume":"50","author":"Kajstura","year":"2001","journal-title":"Diabetes"},{"key":"2022031222485915500_B24","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/sj.bjp.0703740","article-title":"Angiotensin-converting enzyme (ACE) inhibition attenuates insulin-like growth factor-I (IGF-1) induced cardiac fibroblast proliferation","volume":"131","author":"van Eickels","year":"2000","journal-title":"Br J Pharmacol"},{"key":"2022031222485915500_B25","doi-asserted-by":"crossref","first-page":"8630","DOI":"10.1073\/pnas.93.16.8630","article-title":"Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice","volume":"93","author":"Reiss","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022031222485915500_B26","first-page":"59","article-title":"Persistent IGF-1 overexpression in skeletal muscle transiently enhances DNA accretion and growth","volume":"16","author":"Fiorotto","year":"2002","journal-title":"FASEB J"},{"key":"2022031222485915500_B27","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1074\/jbc.M310405200","article-title":"The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway","volume":"279","author":"McMullen","year":"2004","journal-title":"J Biol Chem"},{"key":"2022031222485915500_B28","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.2337\/db07-1808","article-title":"Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes","volume":"57","author":"Soro-Paavonen","year":"2008","journal-title":"Diabetes"},{"key":"2022031222485915500_B29","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/sj.bjp.0707622","article-title":"Knockout of beta(1)- and beta(2)-adrenoceptors attenuates pressure overload-induced cardiac hypertrophy and fibrosis","volume":"153","author":"Kiriazis","year":"2008","journal-title":"Br J Pharmacol"},{"key":"2022031222485915500_B30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1475-2840-6-14","article-title":"Noninvasive and invasive evaluation of cardiac dysfunction in experimental diabetes in rodents","volume":"6","author":"Wichi","year":"2007","journal-title":"Cardiovasc Diabet"},{"key":"2022031222485915500_B31","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.yjmcc.2007.03.900","article-title":"The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo","volume":"42","author":"Ritchie","year":"2007","journal-title":"J Mol Cell Cardiol"},{"key":"2022031222485915500_B32","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1161\/CIRCULATIONAHA.105.595231","article-title":"Akt1 is required for physiological cardiac growth","volume":"113","author":"DeBosch","year":"2006","journal-title":"Circulation"},{"key":"2022031222485915500_B33","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.lfs.2007.05.027","article-title":"Effect of beta-adrenergic and renin-angiotensin system blockade on myocyte apoptosis and oxidative stress in diabetic hypertensive rats","volume":"81","author":"Fiordaliso","year":"2007","journal-title":"Life Sci"},{"key":"2022031222485915500_B34","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.metabol.2005.05.010","article-title":"Elevated glucose activates protein synthesis in cultured cardiac myocytes","volume":"54","author":"Yeshao","year":"2005","journal-title":"Metab Clin Exp"},{"key":"2022031222485915500_B35","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1161\/hh2301.100982","article-title":"Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes","volume":"89","author":"Neri Serneri","year":"2001","journal-title":"Circ Res"},{"key":"2022031222485915500_B36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1042\/bj2820085","article-title":"Stimulation of cardiac protein synthesis by insulin-like growth-factors","volume":"282","author":"Fuller","year":"1992","journal-title":"Biochem J"},{"key":"2022031222485915500_B37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jacc.2005.09.050","article-title":"The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy","volume":"47","author":"Asbun","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2022031222485915500_B38","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.RES.0000065620.39919.20","article-title":"A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes","volume":"92","author":"Candido","year":"2003","journal-title":"Circ Res"},{"key":"2022031222485915500_B39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.diabres.2007.09.014","article-title":"Uncomplicated type 1 diabetes and preclinical left ventricular myocardial dysfunction: insights from echocardiography and exercise cardiac performance evaluation","volume":"79","author":"Palmieri","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031222485915500_B40","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1291\/hypres.30.439","article-title":"Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart","volume":"30","author":"Tsutsui","year":"2007","journal-title":"Hypertens Res"},{"key":"2022031222485915500_B41","doi-asserted-by":"crossref","first-page":"H2237","DOI":"10.1152\/ajpheart.00427.2006","article-title":"Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart","volume":"291","author":"Matsushima","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2022031222485915500_B42","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1007\/s00125-006-0385-2","article-title":"Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus","volume":"49","author":"Westermann","year":"2006","journal-title":"Diabetologia"},{"key":"2022031222485915500_B43","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.freeradbiomed.2005.12.009","article-title":"Metallothionein alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of Ca2+ cycling proteins, NADPH oxidase, poly(ADP-Ribose) polymerase and myosin heavy chain isozyme","volume":"40","author":"Wold","year":"2006","journal-title":"Free Rad Biol Med"},{"key":"2022031222485915500_B44","doi-asserted-by":"crossref","first-page":"H1343","DOI":"10.1152\/ajpheart.01200.2004","article-title":"PKC-\u03f5-dependent survival signals in diabetic hearts","volume":"289","author":"Malhotra","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2022031222485915500_B45","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1093\/emboj\/19.11.2537","article-title":"The conserved phosphoinositide 3-kinase pathway determines heart size in mice","volume":"19","author":"Shioi","year":"2000","journal-title":"EMBO J"},{"key":"2022031222485915500_B46","doi-asserted-by":"crossref","first-page":"12355","DOI":"10.1073\/pnas.1934654100","article-title":"Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy","volume":"100","author":"McMullen","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022031222485915500_B47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1475-2840-7-2","article-title":"Diacylglycerol kinase zeta inhibits myocardial atrophy and restores cardiac dysfunction in streptozotocin-induced diabetes mellitus","volume":"7","author":"Bilim","year":"2008","journal-title":"Cardiovasc Diabetol"},{"key":"2022031222485915500_B48","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc06-9910","article-title":"Physical activity\/exercise and type 2 diabetes: a consensus statement from the American Diabetes Association","volume":"29","author":"Sigal","year":"2006","journal-title":"Diabetes Care"},{"key":"2022031222485915500_B49","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1249\/mss.0b013e318145b642","article-title":"Normalization of diastolic dysfunction in type 2 diabetics after exercise training","volume":"39","author":"Brassard","year":"2007","journal-title":"Med Sci Sports Exerc"},{"key":"2022031222485915500_B50","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2796.2007.01808.x","article-title":"The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study","volume":"262","author":"Fossum","year":"2007","journal-title":"J Intern Med"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/59\/6\/1512\/399098\/zdb00610001512.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/59\/6\/1512\/399098\/zdb00610001512.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:21:14Z","timestamp":1667406074000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/59\/6\/1512\/33387\/Cardiac-Specific-IGF-1-Receptor-Transgenic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,9]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2010,3,9]]},"published-print":{"date-parts":[[2010,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db09-1456","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,9]]}}}